

# CITATION REPORT

List of articles citing

## Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

DOI: 10.3201/eid2203.151430  
Emerging Infectious Diseases, 2016, 22, .

**Source:** <https://exaly.com/paper-pdf/63160723/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
36	The experience of bedaquiline implementation at a decentralised clinic in South Africa. <i>Public Health Action</i> , <b>2016</b> , 6, 190-192	0.9	6
35	Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?. <i>Lancet Infectious Diseases</i> , <b>2017</b> , 17, e429-e433	25.5	8
34	The paradigm shift to end tuberculosis. Are we ready to assume the changes?. <i>Expert Review of Respiratory Medicine</i> , <b>2017</b> , 11, 565-579	3.8	3
33	Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2017</b> , 21, 167-174	2.1	23
32	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , <b>2017</b> ,	35.1	313
31	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	37
30	Xpert <sup>®</sup> MTB/RIF: Usefulness for the diagnosis of tuberculosis and resistance to rifampicin. <i>Medicina Clínica (English Edition)</i> , <b>2017</b> , 149, 399-405	0.3	
29	Bedaquiline or delamanid for rifampin-resistant tuberculosis?. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 772-774	35.1	1
28	Xpert <sup>®</sup> MTB/RIF: Usefulness for the diagnosis of tuberculosis and resistance to rifampicin. <i>Medicina Clínica</i> , <b>2017</b> , 149, 399-405	1	2
27	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 1300-1310	10.2	46
26	Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. <i>Expert Review of Anti-Infective Therapy</i> , <b>2017</b> , 15, 11-21	5.5	16
25	Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 338-353	5.1	71
24	Operational aspects of bedaquiline implementation in Swaziland: report from the field. <i>Public Health Action</i> , <b>2017</b> , 7, 240-242	0.9	3
23	Pan-tuberculosis regimens: an argument against. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 240-242	35.1	10
22	Optimal Management of Drug-Resistant Tuberculosis and Human Immunodeficiency Virus: an Update. <i>Current Treatment Options in Infectious Diseases</i> , <b>2018</b> , 10, 90-106	1	
21	Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR- Strains. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2018</b> , 8, 114	5.9	70
20	Bedaquiline use in South Africa reveals a lifesaving policy in action. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 653-655	35.1	5

19	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet, The</i> , <b>2019</b> , 393, 1331-1384	1384	158
18	Tuberculosis. <i>Lancet, The</i> , <b>2019</b> , 393, 1642-1656	40	257
17	Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. <i>Public Health Action</i> , <b>2019</b> , 9, 32-41	0.9	1
16	Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. <i>Public Health Action</i> , <b>2019</b> , 9, S73-S79	0.9	5
15	Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences. <i>European Respiratory Review</i> , <b>2019</b> , 28,	9.8	1
14	Transmission of drug-resistant tuberculosis in HIV-endemic settings. <i>Lancet Infectious Diseases, The</i> , <b>2019</b> , 19, e77-e88	25.5	27
13	Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e3391-e3397	11.6	12
12	Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , <b>2020</b> , 98, 420-439	10.5	8
11	Mechanisms of development of medicine stability Mycobacterium tuberculosis: is there a chance to win?. <i>Pulmonologiya</i> , <b>2021</b> , 31, 100-108	0.8	0
10	COMPASSIONATE USE OF INVESTIGATIONAL DRUG DURING EMERGENCY CONDITIONS AND ASSOCIATED ETHICAL ASPECTS, CHALLENGES, AND BENEFITS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 5-12	0.4	
9	Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. <i>Antimicrobial Resistance and Infection Control</i> , <b>2021</b> , 10, 126	6.2	2
8	Tuberculosis innovations mean little if they cannot save lives. <i>ELife</i> , <b>2017</b> , 6,	8.9	26
7	Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies. <i>Emerging Topics in Life Sciences</i> , <b>2020</b> , 4, 581-600	3.5	4
6	The potential perils of a drug protection framework in tuberculosis. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> ,	25.5	
5	Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 1222	4	0
4	Re-Evaluating the Merits of Decentralisation as a Core Strategy for Effective Delivery of Drug-Resistant Tuberculosis Care in Pakistan.. <i>Health Policy and Planning</i> , <b>2022</b> ,	3.4	
3	Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study. <b>2022</b> , 66,		0
2	Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis - insights from a qualitative study.		0

- 1 Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study. **2022**, 22,

o